Companies / Health Care
ILMN
Illumina, Inc.
Life Sciences Tools & Services
Life Sciences Tools & ServicesAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health72
Growth21
Profitability73
Cash generation88
Balance sheet100
Dilution control76
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-27)4.2%Revenue growth (FY)-0.7%Revenue CAGR (3y)-1.8%Gross margin66.1%Operating margin18.6%Net margin19.6%Free cash flow margin21.4%R&D / revenue22.3%Stock comp / revenue6.3%Net debt / operating cash flow—Current ratio2.08Diluted share count change-1.9%
| Fiscal year ending | FY 2022-01 | FY 2023-01 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $4.5B | $4.6B | $4.5B | $4.4B | $4.3B |
| Gross profit | $3.2B | $3.0B | $2.7B | $2.9B | $2.9B |
| Operating income | -$123M | -$4.2B | -$1.1B | -$833M | $807M |
| Net income | $762M | -$4.4B | -$1.2B | -$1.2B | $850M |
| Operating cash flow | $545M | $392M | $478M | $837M | $1.1B |
| Capital expenditure | $208M | $286M | $195M | $128M | $148M |
| Free cash flow | $337M | $106M | $283M | $709M | $931M |
| R&D | $1.2B | $1.3B | $1.4B | $1.2B | $967M |
| Stock-based comp | $754M | $366M | $380M | $370M | $275M |
| Buybacks | $0 | $0 | $0 | $116M | $742M |
| Cash | $1.2B | $2.0B | $1.0B | $1.1B | $1.4B |
| Equity | $10.7B | $6.6B | $5.7B | $2.4B | $2.7B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.